Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-03-09	0.0438 $	+5.54%	102,298
26-03-06	0.0415 $	-1.52%	54,402
26-03-05	0.0421 $	+5.09%	40,325
26-03-04	0.0401 $	-4.52%	34,077
26-03-03	0.0420 $	+0.48%	18,652

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 03:53:07 2026-03-09 pm EDT			5-day change	1st Jan Change
0.0438 ^USD	+5.54%		+4.78%	+1.86%

Mar. 05	Liberate Bio Secures Exclusive and Non-Exclusive Licenses to Myeloid-Optimized Car Design Patents from Carisma Therapeutics and the University of Pennsylvania	CI
Feb. 04	Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor	CI

Capitalization	1.8M 1.55M 1.4M 1.34M 2.44M 166M 2.55M 16.55M 6.64M 79.3M 6.75M 6.61M 285M	P/E ratio 2023	-1.13x	P/E ratio 2024	-0.29x
Enterprise value	-14.55M -12.55M -11.34M -10.86M -19.75M -1.34B -20.65M -134M -53.67M -641M -54.63M -53.46M -2.3B	EV / Sales 2023	2,933,403x	EV / Sales 2024	57,658x
Free-Float	70.12%	Yield 2023 *	-	Yield 2024	-

Mar. 05	Liberate Bio Secures Exclusive and Non-Exclusive Licenses to Myeloid-Optimized Car Design Patents from Carisma Therapeutics and the University of Pennsylvania	CI
Feb. 04	Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor	CI
Nov. 12	Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-15	Carisma Therapeutics - CEO Steven Kelly to leave effective November 15 - SEC filing	RE
25-10-15	Carisma Therapeutics, Inc. Announces Termination of Steven Kelly as Chief Executive Officer, Effective November 15, 2025	CI
25-10-15	Carisma Therapeutics, Inc. Announces Management Resignations	CI
25-10-14	Carisma Therapeutics, Inc.(NasdaqCM:CARM) dropped from S&P TMI Index	CI
25-10-09	Carisma Therapeutics, Inc.(OTCPK:CARM) dropped from NASDAQ Composite Index	CI
25-09-18	Carisma Therapeutics & Modernatx amend collaboration and license agreement - SEC filing	RE
25-09-15	OrthoCellix cancelled the acquisition of Carisma Therapeutics, Inc. from group of shareholders in a reverse merger transaction.	CI
25-08-07	Carisma Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-23	OrthoCellix, Inc. entered into an agreement to Carisma Therapeutics, Inc. in a reverse merger transaction.	CI
25-06-23	Carisma Therapeutics to Merge With OrthoCellix in All-Stock Transaction	MT

24-12-16	HC Wainwright Downgrades Carisma Therapeutics to Neutral From Buy	MT
24-12-12	Baird Downgrades Carisma Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $10	MT
24-12-10	BTIG Downgrades Carisma Therapeutics to Neutral From Buy	MT
24-04-11	BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target	MT
24-04-02	HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating	MT

Carisma Therapeutics, Inc. Stock

Equities

CARM

US14216R1014

Biotechnology & Medical Research

Valuation: Carisma Therapeutics, Inc.

Chart: Carisma Therapeutics, Inc.

Latest news: Carisma Therapeutics, Inc.

Analysts' recommendations: Carisma Therapeutics, Inc.

Press Releases: Carisma Therapeutics, Inc.

News in other languages: Carisma Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Carisma Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Dec. 05	Carisma Announces Delisting from Nasdaq and SEC Deregistration	PR
25-03-31	Carisma Therapeutics Provides Corporate Updates	PR
25-02-19	Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference	PR
25-02-05	Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference	PR
24-11-27	Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	PR

23-01-02	MORNING BRIEFING - USA/Asien
23-01-02	MORNING BRIEFING - Deutschland/Europa
22-12-30	MÄRKTE USA/Wall Street beendet schwaches Börsenjahr knapp behauptet
22-12-30	MÄRKTE USA/Leichter - Schwächstes Börsenjahr seit 2008
22-12-30	MÄRKTE USA/Schwächer - Anleihen mit historisch schlechtem Jahr

1 day	+5.54%
1 week	+4.78%
Current month	+2.34%
1 month	+10.89%
3 months	-35.40%
6 months	-89.42%
Current year	+1.86%

1 week	0.04	0.04
1 month	0.04	0.05
Current year	0.03	0.05
1 year	0.03	1.27
3 years	0.03	9.77
5 years	0.03	9.77
10 years	0.03	9.77

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
CARISMA THERAPEUTICS, INC.	+5.54%	+4.78%	-90.23%	-98.79%	1.83M
ARGENX SE	+1.14%	-0.99%	+20.11%	+97.34%	44.74B
WUXI APPTEC CO., LTD.	-2.36%	-5.14%	+45.74%	+12.82%	39.46B
INSMED INCORPORATED	+2.14%	-2.18%	+91.12%	+653.32%	30.85B
BIONTECH SE	+0.65%	-4.95%	-6.09%	-19.74%	25.64B
WUXI BIOLOGICS (CAYMAN) INC.	+3.39%	-1.03%	+54.19%	-29.58%	18.74B
GENMAB A/S	+2.42%	+0.08%	+16.13%	-28.27%	16.45B
AKESO, INC.	+10.90%	+15.52%	+64.76%	+192.62%	12.22B
SUMMIT THERAPEUTICS INC.	+4.04%	-2.90%	-11.59%	+1,007.04%	12.19B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.84%	+17.70%	+68.13%	-	11.33B
Average	+1.60%	-2.68%	+25.23%	+198.53%	21.16B
Weighted average by Cap.	-0.52%	-3.56%	+38.10%	+190.32%

	2023	2024
Net sales	14.92 12.87 11.62 11.14 20.24 1.37K 21.16 137.2 55.02 657.47 56 54.8 2.36K	19.63 16.93 15.29 14.66 26.64 1.81K 27.85 180.55 72.4 865.17 73.7 72.11 3.1K
Net income	-86.88M -74.94M -67.67M -64.86M -118M -8B -123M -799M -320M -3.83B -326M -319M -13.74B	-60.48M -52.17M -47.11M -45.15M -82.05M -5.57B -85.79M -556M -223M -2.67B -227M -222M -9.56B
Net Debt	-74.48M -64.25M -58.02M -55.6M -101M -6.86B -106M -685M -275M -3.28B -280M -274M -11.78B	-16.35M -14.11M -12.74M -12.21M -22.19M -1.51B -23.2M -150M -60.31M -721M -61.39M -60.07M -2.59B